Business
AxisBiotix-Ps™ to launch on Amazon UK
AxisBiotix-Ps™ to launch on Amazon UK.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n\nSkinBioTherapeutics plc\n(\"SkinBioTherapeutics\" or \"the Company\")\nAxisBiotix-Ps™ to launch on Amazon UK\n \n30 November 2023 - SkinBioTherapeutics plc, (AIM: SBTX, or the \"Company\"), the life science business focused on skin health announces that its AxisBiotix-Ps™ food supplement will launch on Amazon.co.uk from Wednesday, 6 December 2023 at 9am.\n \nThe launch of a sales channel through Amazon is a key part of the commercialisation strategy to expand market share for AxisBiotix-Ps™. The first Amazon launch is in the UK; the aim is then to extend product availability through other Amazon country sites. Management is already proactively seeking to expand online sales of its AxisBiotix-Ps™ into the European countries where the product has regulatory clearance (France, Italy and Spain).\n \nAxisBiotix-Ps™ first went on sale to UK in October 2021 and is intended for customers to alleviate sensitive skin conditions such as psoriasis. The response from customers continues to be very positive with the retention rates of AxisBiotix-Ps™ in the UK staying at 80% or above. If access to the product can be made simpler, via an online channel like Amazon which is familiar to the majority of people, then management believes this will boost sales and marketing efforts.\n \nAccording to Mintel, approximately 90% of the UK adult population uses Amazon. In 2019 alone, the UK e-commerce market was the largest in Europe and third largest to China and the US. Amazon held 30% of this market, and has shown ambitions in the beauty and skincare markets, with the launch of its own-brand skin care line, Belei. It has also teamed up with beauty major, L'Oreal.\n \nStuart J. Ashman, CEO of SkinBioTherapeutics, said: \"The skin care market is a significant market, with an increasing global focus on health and well-being, and the demand for science-backed supplements is at an all-time high. The primary focus for AxisBiotix-Ps™ is growing our share of the market and using a sales channel like Amazon, which we use everyday, makes good strategic sense. We hope to announce the European launches on Amazon before the end of the year.\"\n \n-Ends-\n \n\n\n\n\nFor more information please contact:\n \n\n\n\n\nSkinBioTherapeutics plc\nStuart J. Ashman, CEO\nManprit Randhawa, CFO\n \n\n\nTel: +44 (0)...